Capricor Therapeutics Inc. (CAPR)
NASDAQ
Closed
Aug 25, 2026
Day's Range
7.2752 wk Range
2.96Overview - CAPR - Capricor Therapeutics Inc.
Key Statistics
Valuation
Enterprise Value
248.45M
P/E (Trailing)
‪-3.67‬
P/E (Forward)
‪-4.82‬
PEG Ratio
‪-0.32‬
Price / Book
‪1.80‬
EV / EBITDA
‪-1.86‬
Profitability
Profit Margin
‪0.00%‬
Operating Margin
‪0.00%‬
Return on Assets
‪-33.63%‬
Return on Equity
‪-73.70%‬
Ownership
Shares Outstanding
57.66M
Float
45.54M
Short % of Shares Outstanding
‪30.49%‬
Held by Insiders
‪9.43%‬
Held by Institutions
‪76.06%‬
Price stats
Beta
‪0.52‬
50-Day Avg
‪15.94‬
200-Day Avg
‪23.21‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
10 analysts
Average price target
‪$ 10.50‬Shariah Compliance
Report Date: Feb 20, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - CAPR - Capricor Therapeutics Inc.
Peers - CAPR - Capricor Therapeutics Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- CAPRNASDAQCapricor Therapeutics Inc.365.69MMarket Cap+5.31%52-week change-3.09P/E (Trailing)‪0.00%‬Profit Margin
- ARGXNASDAQargenx SE American Depositary Receipt63.39BMarket Cap+30.55%52-week change39.65P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals Inc32.12BMarket Cap-87.94%52-week change40.23P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE28.34BMarket Cap+7.12%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S16.52BMarket Cap+21.81%52-week change19.30P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma, Inc.15.71BMarket Cap+38.32%52-week change-21.28P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBiomarin Pharmaceutical Inc.12.59BMarket Cap+11.71%52-week change180.27P/E (Trailing)‪2.14%‬Profit Margin
Profile Summary - CAPR - Capricor Therapeutics Inc.
About
Capricor Therapeutics Inc. is a clinical-stage biotechnology company focused on developing cell and exosome-based therapeutics for rare diseases with high unmet medical need. The company concentrates particularly on Duchenne muscular dystrophy, targeting both skeletal and cardiac muscle complications associated with…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
